https://doi.org/10.4081/monaldi.2024.3149
Optimal treatment strategies for coronary heart disease in cancer patients: a complex clinical case
Published: September 12, 2024
Abstract Views: 176
PDF_EARLY VIEW: 88
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Coronary heart disease (CHD) remains a leading cause of mortality among cancer patients, primarily due to shared risk factors and the impacts of chemotherapeutic drugs, immune checkpoint inhibitors, and radiotherapy. Determining the optimal treatment strategy remains a challenging issue for patients with concurrent CHD and malignant neoplasms. In high-risk patients, managing CHD frequently takes precedence over addressing the oncologic disease. Myocardial revascularization, coupled with optimal medical therapy for CHD, can significantly enhance patient survival by reducing the risks of myocardial infarction and sudden cardiac death. However, selecting a surgical treatment strategy requires careful consideration of the indications, the complexity of coronary lesions, the risk of bleeding and thrombosis, and the overall prognosis of the malignancy. This clinical case demonstrates the importance of risk-benefit assessment, multidisciplinary discussion of cure strategy, and application of novel technologies to provide the most personalized and effective treatment.
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63.
DOI: https://doi.org/10.3322/caac.21834
Davydov MI, Akchurin RS, Gerasimov SS, et al. Simultaneous surgery of competing cardio-vascular and malignant diseases of lungs and mediastinum. Khirurgiia 2010;8:4-10. [Article in Russian].
Rupprecht S, Finn S, Hoyer D, et al. Association between systemic inflammation, carotid arteriosclerosis, and autonomic dysfunction. Transl Stroke Res 2020;11:50-9.
DOI: https://doi.org/10.1007/s12975-019-00706-x
Buziashvili YI, Asymbekova EU, Matskeplishvili ST, et al. Dynamics of echocardiographic parameters during neoadjuvant chemotherapy in patients with breast cancer. Creative Cardiology 2022;16:520-32.
Mamas MA, Brown SA, Sun LY. Coronary artery disease in patients with cancer: it's always the small pieces that make the bigger picture. Mayo Clin Proc 2020;95:1819-21.
DOI: https://doi.org/10.1016/j.mayocp.2020.07.006
Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation 2019;139:e997-1012.
DOI: https://doi.org/10.1161/CIR.0000000000000679
Laenens D, Yu Y, Santens B, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol 2022;40:3430-8.
DOI: https://doi.org/10.1200/JCO.21.01808
Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229-361. Erratum in: Eur Heart J 2023;44:1621.
DOI: https://doi.org/10.1093/eurheartj/ehad196
Sarkar B. An incorrect impression of dose versus the ischemic cardiac toxicity risk profile for breast and chest wall radiation therapy. Int J Radiat Oncol Biol Phys 2020;106:451-2.
DOI: https://doi.org/10.1016/j.ijrobp.2019.11.006
Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41.
DOI: https://doi.org/10.1016/j.jacc.2007.06.037
Golukhova EZ, Slivneva IV, Kozlova OS, et al. Treatment strategies for chronic coronary heart disease with left ventricular systolic dysfunction or preserved ejection fraction-a systematic review and meta-analysis. Pathophysiology 2023;30:640-58.
DOI: https://doi.org/10.3390/pathophysiology30040046
Iannaccone M, D'Ascenzo F, Vadalà P, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care 2018;7:631-8.
DOI: https://doi.org/10.1177/2048872617706501
Kwok CS, Wong CW, Kontopantelis E, et al. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur. Heart J 2021;42:1019-34.
DOI: https://doi.org/10.1093/eurheartj/ehaa1032
Guo W, Fan X, Lewis BR, et al. Cancer patients have a higher risk of thrombotic and ischemic events after percutaneous coronary intervention. JACC Cardiovasc Interv 2021;14:1094-105.
DOI: https://doi.org/10.1016/j.jcin.2021.03.049
Ueki Y, Vögeli B, Karagiannis A, et al. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC CardioOncol 2019;1:145-55.
DOI: https://doi.org/10.1016/j.jaccao.2019.11.001
Thomason N, Monlezun DJ, Javaid A, et al. Percutaneous coronary intervention in patients with gynecological cancer: machine learning-augmented propensity score mortality and cost analysis for 383,760 patients. Front Cardiovasc Med 2022;8:793877.
DOI: https://doi.org/10.3389/fcvm.2021.793877
Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med 2018;7:265-73.
DOI: https://doi.org/10.21037/apm.2017.11.01
Han XJ, Li JQ, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med 2020;5:221-33.
DOI: https://doi.org/10.1016/j.cdtm.2019.12.007
Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2021;42:308-19.
DOI: https://doi.org/10.1093/eurheartj/ehaa739
Ahmed T, Pacha HM, Addoumieh A, et al. Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents. Front Cardiovasc Med 2022;9:901431.
DOI: https://doi.org/10.3389/fcvm.2022.901431
How to Cite
Golukhova, Elena Zelikovna, Inessa Viktorovna Slivneva, Andrey Lvovich Pylev, Olga Sergeevna Kozlova, Karen Valerievich Petrosyan, Denis Sergeevich Romanov, and Alexander Yurievich Volkov. 2024. “Optimal Treatment Strategies for Coronary Heart Disease in Cancer Patients: A Complex Clinical Case”. Monaldi Archives for Chest Disease, September. https://doi.org/10.4081/monaldi.2024.3149.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Andrea Segreti, Sara Mastroberardino, Lorenzo Frau, Alessandro Appetecchia, Luca D’Antonio, Danilo Ricciardi, Gian Paolo Ussia, Francesco Grigioni, Severe heart failure and intracardiac thrombosis: going beyond the appearance for diagnosis and treatments , Monaldi Archives for Chest Disease: Early Access
- Giovanni Rossi, Mario Perrillo, Martina Flora, Adriano Costigliola, Mariano Mollica, Carlo Iadevaia, Giampiero Gaio, Francesco S. Cerqua, Andrea Bianco, Fabio Perrotta, Incidental diagnosis and therapeutic approach of an iatrogenic intra-parenchymal pulmonary intercostal artery pseudoaneurysm: a case report , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
- Marco Moscarelli, Ruggero De Paulis, The phyllotaxis of the aortic valve , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
- Silvia Porcu, Antonella Mandas, How to evaluate Quality of Life , Monaldi Archives for Chest Disease: Vol. 89 No. 1 (2019)
- Marika Werren, Roberto Copetti, Nicola Gaibazzi, Franco Giada, Andrea Faggiano, Chiara Ricci, Pompilio Faggiano, Choosing wisely in cardiology: Five proposals from the Italian Association for Cardiovascular Prevention and Rehabilitation , Monaldi Archives for Chest Disease: Vol. 89 No. 2 (2019)
- Kenan Yalta, Ertan Yetkin, Tulin Yalta, Systemic inflammation in patients with Takotsubo syndrome: a review of mechanistic and clinical implications , Monaldi Archives for Chest Disease: Vol. 91 No. 2 (2021)
- Afrah Alsomali, Abdullah Eltayeb, Sarah Aldosari, Maie AlShahid, Aly AlSanei, Ali AlEnazy, Olga Vriz, Recurrence of left ventricular pseudoaneurysm after multiple mitral valve replacements , Monaldi Archives for Chest Disease: Vol. 92 No. 2 (2022)
- Olga Vriz, Talal Alzahrani, Irene Landi, Ali Hassan Mushtaq, Abdullah Shaik, Ahmed Nahid Elshaer, Age-sex effect on in-hospital complications and mortality in patients with Takotsubo syndrome. Insights from the National Inpatient Sample , Monaldi Archives for Chest Disease: Vol. 94 No. 1 (2024)
- Georgia-Emmanuela Dendrinou, Panagiotis Zagarelos, Angelos Sofronas, Stamatis Katsenos, Primary pulmonary lymphangiectasia in Noonan syndrome: apropos of an extremely rare manifestation and a brief literature review , Monaldi Archives for Chest Disease: Vol. 90 No. 4 (2020)
- Ilaria Cavazzana, Enrico Vizzardi, Franco Franceschini, Diastolic dysfunction in rheumatoid arthritis: a usual travel-mate? , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
<< < 51 52 53 54 55 56 57 58 59 60 > >>
You may also start an advanced similarity search for this article.
